What does the evidence say about Lutein Visual Performance Randomized Trial?

The current Migaku evidence database contains 2 reusable source documents for Lutein Visual Performance Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation. - However, these approaches require repeated invasive injections and are associated with considerable economic burden and procedural risks [,]. [Wang Wei-Xiang (2026); evidence level 1] - Experimental and clinical studies have suggested that increased macular pigment levels may support visual performance and potentially attenuate AMD progression [–]. [Wang Wei-Xiang (2026); evidence level 1] - Some findings from the Age‐Related Eye Disease Study 2 (AREDS2) indicated that lutein and zeaxanthin supplementation significantly reduced the risk of progression to late‐stage AMD []. [Wang Wei-Xiang (2026); evidence level 1] - 1 2 3 4 5 6 7 Age‐related macular degeneration (AMD) remains one of the leading causes of irreversible central vision loss among individuals over 65 years of age worldwide. [Wang Wei-Xiang (2026); evidence level 1] - This systematic review aimed to evaluate randomized controlled trial (RCT) evidence on the effects of carotenoids, anthocyanins, polyunsaturated fatty acids, and combined nutraceutical formulations on refractive outcomes, axial length, macular pigment optical density (MPOD), visual function, and symptoms of visual fatigue. [Martinez-Perez C (2025); evidence level 1] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.